RxDoctor Payments Data

Theodore Yuo, MD

Surgery · Pittsburgh, PANPI 1588829196

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,442 of the $14,457 with a category attached, or 72.2%. 14 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 56.3% of the total. Reporting peaked in 2021 at $9,003 and has fallen 92.9% since, to $636 in 2025. Among surgery clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,457in general payments, 2019–2025

Across 62 payments — averaging $233.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$8K
  • Merit Medical Systems Inc$3K
  • Medtronic$1K
  • W. L. Gore & Associates, Inc.$1K
  • Penumbra, Inc.$339
  • Inari Medical, Inc.$153
  • plus $356 from 8 others
$73,093in research payments, 2019–2025

Across 24 payments — averaging $3045.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merit Medical Systems Inc$73K

What the payments were for

  • Consulting fees$10,44272%
  • Speaking & faculty fees$3502%
  • Travel & lodging$1,0357%
  • Food & beverage$2,63018%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,457 in reported general payments places this provider in the 90th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$94,737
Medicare patients
480
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$52,982
Enoxaparin Sodium11$2,022
ClopidogrelClopidogrel Bisulfate48$565
Cilostazol14$238
Oxycodone Hcl49$90
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$33
Prednisone24$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$52,98271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,424 surgery providers in Pennsylvania.

Other surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →